RA Capital Management L.P. Buys New Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

RA Capital Management L.P. bought a new stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 3,181,818 shares of the company's stock, valued at approximately $23,705,000. RA Capital Management L.P. owned approximately 4.66% of EyePoint Pharmaceuticals at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Geode Capital Management LLC increased its holdings in EyePoint Pharmaceuticals by 16.1% in the 3rd quarter. Geode Capital Management LLC now owns 1,199,056 shares of the company's stock worth $9,583,000 after acquiring an additional 166,699 shares during the last quarter. Barclays PLC lifted its position in EyePoint Pharmaceuticals by 410.4% in the 3rd quarter. Barclays PLC now owns 245,045 shares of the company's stock worth $1,959,000 after buying an additional 197,033 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of EyePoint Pharmaceuticals by 1,171.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 371,758 shares of the company's stock worth $2,970,000 after acquiring an additional 342,516 shares during the last quarter. Franklin Resources Inc. boosted its position in EyePoint Pharmaceuticals by 9.9% during the 3rd quarter. Franklin Resources Inc. now owns 4,012,048 shares of the company's stock valued at $32,056,000 after buying an additional 362,399 shares during the period. Finally, abrdn plc purchased a new position in EyePoint Pharmaceuticals during the 4th quarter valued at $1,719,000. 99.41% of the stock is owned by institutional investors.

EyePoint Pharmaceuticals Price Performance

Shares of NASDAQ:EYPT traded down $0.51 during midday trading on Tuesday, reaching $6.36. 364,774 shares of the company's stock were exchanged, compared to its average volume of 875,871. EyePoint Pharmaceuticals, Inc. has a fifty-two week low of $3.91 and a fifty-two week high of $14.00. The stock has a market cap of $437.29 million, a price-to-earnings ratio of -3.17 and a beta of 1.39. The firm's 50 day simple moving average is $6.02 and its two-hundred day simple moving average is $7.60.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last announced its quarterly earnings data on Wednesday, March 5th. The company reported ($0.64) EPS for the quarter, missing analysts' consensus estimates of ($0.54) by ($0.10). The firm had revenue of $11.60 million during the quarter, compared to analysts' expectations of $11.02 million. EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. Equities research analysts predict that EyePoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have commented on EYPT. StockNews.com raised EyePoint Pharmaceuticals to a "sell" rating in a report on Friday, March 14th. HC Wainwright restated a "buy" rating and set a $22.00 target price on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. Citigroup started coverage on shares of EyePoint Pharmaceuticals in a research report on Tuesday, January 7th. They set a "buy" rating and a $33.00 price objective on the stock. Finally, Chardan Capital reiterated a "buy" rating and set a $33.00 price objective on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. One analyst has rated the stock with a sell rating and nine have given a buy rating to the stock. According to data from MarketBeat, EyePoint Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $26.63.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.